Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989) and Everolimus (RAD001) in Patients With Advanced Solid Tumors

NCT00352443 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT00352443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00352443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989) and Everolimus (RAD001) in Patients With Advanced Solid Tumors
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2006
Completion date
September 30, 2013
Enrollment
66 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, unspecified adult solid tumor, protocol specific